Last reviewed · How we verify

NCT03492801

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Terminated Last updated 9 January 2024
What this trial tests

trial testing Biospecimen Collection in Stage III Non-Small Cell Lung Cancer AJCC v7 in 10 participants. Terminated before completion.

Timeline
11 December 2017
Primary endpoint
21 November 2023
21 November 2023

Quick facts

Lead sponsorUniversity of Southern California
StatusTerminated
Study typeOBSERVATIONAL
Enrollment10
Start date11 December 2017
Primary completion21 November 2023
Estimated completion21 November 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Stage III Non-Small Cell Lung Cancer AJCC v7 or Stage IIIA Non-Small Cell Lung Cancer AJCC v7. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery. Collecting blood samples may help measure the changes in lung cancer, better learn methods to track cancer in the bloodstream, and improve cancer treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

Other University of Southern California trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03492801.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing